Biote Schedules First Quarter 2023 Financial Results Release and Conference Call

Rhea-AI Summary

biote Corp. (Nasdaq: BTMD) announced that it will release its first quarter financial results on May 9, 2023, after market close. A conference call to discuss these results is set for May 10, 2023, at 8:30 a.m. ET. Investors can access the call via phone or a live webcast. Biote specializes in personalized hormone optimization therapies aimed at transforming healthy aging. The company operates within an $8 billion global market, focusing on training practitioners to address hormone-related aging conditions. The press release also includes forward-looking statements highlighting various risks, such as regulatory pressures and competition. Investors are encouraged to review Biote's Annual Report and other SEC filings for further details on risks and uncertainties.

Positive

• Company operates within an $8 billion global market.
• Focus on training practitioners can enhance clinic success.

Negative

• Future business growth may be impacted by heavy competition.
• Regulatory challenges could hinder operational success.

IRVING, Texas--(BUSINESS WIRE)-- biote Corp. (Nasdaq: BTMD) (“Biote” or the “Company”), a leading provider of preventive health care through the delivery of personalized hormone therapy, today announced the Company will provide first quarter financial results on Tuesday, May 9, 2023, after the close of the market. A conference call to discuss the firm’s results will be held Wednesday, May 10, 2023, at 8:30 a.m. ET.

Conference Call Details

The conference call may be accessed by dialing (844) 481-2820 (U.S toll-free) or (412) 317-0679 (International). The live webcast of the call can be accessed using the following link: biote Corp. First Quarter Earnings Call. A replay of the webcast will be available on the Events page of the Biote Investor Relations website, found here, shortly after the event concludes.

About Biote

Biote is transforming healthy aging through innovative, personalized hormone optimization therapies delivered by Biote-certified medical providers. Biote trains practitioners how to identify and treat early indicators of hormone-related aging conditions, an underserved $8 billion global market, providing affordable symptom relief for patients and driving clinic success for practitioners.

Forward-Looking Statements

This press release contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Some of the forward-looking statements can be identified by the use of forward-looking words. Statements that are not historical in nature, including the words “may,” “can,” “should,” “will,” “estimate,” “plan,” “project,” “forecast,” “intend,” “expect,” “hope,” “anticipate,” “believe,” “seek,” “target,” “continue,” “could,” “might,” “ongoing,” “potential,” “predict,” “would” and other similar expressions, are intended to identify forward-looking statements. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual results or developments to differ materially from those expressed or implied by such forward-looking statements, including but not limited to: the success of our dietary supplements to attain significant market acceptance among clinics, practitioners and their patients; our customers’ reliance on certain third parties to support the manufacturing of bio-identical hormones for prescribers; our and our customers’ sensitivity to regulatory, economic, environmental and competitive conditions in certain geographic regions; our ability to increase the use by practitioners and clinics of the Biote Method at the rate that we anticipate or at all; our ability to grow our business; the significant competition we face in our industry; our limited operating history; our ability to protect our intellectual property; the heavy regulatory oversight in our industry; changes in applicable laws or regulations; the inability to profitably expand in existing markets and into new markets; the possibility that we may be adversely impacted by other economic, business and/or competitive factors; and future exchange and interest rates. The foregoing list of factors is not exhaustive. You should carefully consider the foregoing factors and the other risks and uncertainties described in the “Risk Factors” section of Biote’s Annual Report on Form 10-K for the fiscal year ended December 31, 2022 filed with the SEC on March 29, 2023, and other documents filed by Biote from time to time with the Securities and Exchange Commission. These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and Biote assumes no obligation and does not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise. Biote does not give any assurance that it will achieve its expectations.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230426005006/en/

Media

Press@biote.com



Investors

IR@biote.com

Source: biote Corp.

FAQ

When will biote Corp. announce its first quarter earnings?

biote Corp. will announce its first quarter earnings on May 9, 2023.

What time is the biote Corp. conference call for earnings discussion?

The conference call will take place on May 10, 2023, at 8:30 a.m. ET.

What is biote Corp.'s business focus?

Biote Corp. focuses on personalized hormone optimization therapies to facilitate healthy aging.